Reference to 'New Leaf team' managing investments for 'NLV-III'.
HOUSE_OVERSIGHT_024055.jpg
This document appears to be a page from an investment memorandum for 'NLV-III' (New Leaf Ventures III). It outlines the 'New Leaf' team's due diligence process, risk assessment factors (such as IP strength and regulatory risks), and team-oriented management philosophy. It also details the intended portfolio composition, targeting 24-28 companies with a specific asset allocation focused heavily on biopharmaceuticals (50-60%).
Entities connected to both New Leaf and NLV-III
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein relationship